In the United States, doctors often perform a low-dose dose of aspirin for people between the ages of 50 and 70 to prevent heart attacks and locks (ACV), even if they have never suffered from similar illnesses.
In Europe, cardiologists do this only after a first heart problem.
Aspirin The blood fluidizes and prevents the spotting of the arteries from forming. But too much blood can become lightning. As a result, the dilemma is: for what type of patient does the benefit of reducing cardiovascular risk have the full effect of blood?
For people who have already had a stroke or heart attack, it is well-balanced to record aspirin, according to many studies. These people have a clear risk of a second accident, and aspirin helps prevent it.
A new study, submitted on Tuesday Journal of the American Medical Association (Jama), offers a wider vision for patients who have no cardiovascular problems yet.
But it really is not the controversy: it states that, at one point in time, aspiring to risk reigns and sticks in people with no history; but, on the other hand, increases the risk of severe bleeding, especially in the brain, stomach and intestine.
Aspirin does not affect any mortality in any way.
"For healthy people, the low benefits of aspirin for sending sticks and heart attacks have a counterpart in an increased chance of blood," says Jane Armitage, professor of epidemiology at Oxford University.
As a conclusion, Doctors have to attack aspirin spirit, depending on the other risks of a patient, the cardiologist Michael Gaziano writes in a response.
For example, by cycling or lowering cholesterol levels, other methods of attempting to reduce cardiovascular risk are included.
This new study is a meta-analysis, which means that the two authors of King's College London study the 13 major clinical issues on the subject from 1988 to 2018 and include conclusions based on all these tests.
This method makes it possible to connect the uncertainties with each study and more generally to identify a general effect based on 164,000 people who do not participate in the total meetings.
The surprise is that researchers they found no link between aspirin and the reduction in the number of cancer cases, Contrary to what more and more studies have shown, aspirin increases the risk for certain chancers, especially colorectal cancer.
So much so that the Workgroup includes & # 39; A United States (United States Provisional Service Task Force), a body that contains recommendations from public health, contains, since 2016, the daily entry of aspirin into people from 50 to 69 years of age to, inter alia, the incidence of this cancer increase.
With information from AFP